AFT PHARMACEUTICALS LIMITED — Director's Dealing 2021

Jul 13, 2021

==> picture [114 x 29] intentionally omitted <==

Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

==> picture [536 x 671] intentionally omitted <==

----- Start of picture text ----- To NZX Limited; andName of listed issuer: AFT Pharmaceuticals Limited (AFT)Date this disclosure made: 14-Jul-21Date of last disclosure: n/aDirector or senior manager giving disclosureFull name(s): Louise ClaytonName of listed issuer: AFT Pharmaceuticals Limited (AFT)Name of related body corporate (if applicable): Not applicablePosition held in listed issuer: Director International BusinessSummary of acquisition or disposal of relevant interest (excluding specified derivatives)1. Unlisted options to acquire Fully-Paid Ordinary Shares inClass of affected quoted financial products: AFT (Ordinary Shares)2. Ordinary Shares in AFTNature of the affected relevant interest(s): Registered holder and beneficial interestFor that relevant interest-1. 40,000 unlisted optionsNumber held in class before acquisition or disposal: 2. 10,000 Ordinary Shares1. 25,000 unlisted optionsNumber held in class after acquisition or disposal: 2. 25,000 ordinary sharesCurrent registered holder(s): Louise ClaytonRegistered holder(s) once transfers are registered: Louise ClaytonDetails of transactions giving rise to acquisition or disposalTotal number of transactions to which notice relates: 1Details of transactions requiring disclosure-Date of transaction: 14-Jul-21Exercise of 15,000 unlisted options and issue of 15,000Nature of transaction: Ordinary Shares pursuant to AFT Share Option PlanName of any other party or parties to the transaction (if known):The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal.If the consideration was not in cash and cannot be readily by converted into a cash value, describethe consideration: Exercise price of NZ$2.80 per share / $42,000.00Number of financial products to which the transaction related: 15,000If the issuer has a financial products trading policy that prohibits directors or senior managers fromtrading during any period without written clearance (a closed period) include the following details—Whether relevant interests were acquired or disposed of during a closed period: Not applicableWhether prior written clearance was provided to allow the acquisition or disposal to proceed duringthe closed period: Not applicableDate of the prior written clearance (if any): Not applicableSummary of other relevant interests after acquisition or disposal:Class of quoted financial products: Not applicableNature of relevant interest: Not applicableFor that relevant interest,-Number held in class: Not applicableCurrent registered holder(s): Not applicableFor a derivative relevant interest,-Type of derivative: Not applicableDetails of derivative,-The notional value of the derivative (if any) or the notional amount of underlying financial products (ifany): Not applicableA statement as to whether the derivative is cash settled or physically settled: Not applicableMaturity date of the derivative (if any): Not applicableExpiry date of the derivative (if any): Not applicableThe price's specified terms (if any): Not applicableAny other details needed to understand how the amount of the consideration payable under thederivative or the value of the derivative is affected by the value of the underlying financial products: Not applicableFor that derivative relevant interest,-Parties to the derivative: Not applicableIf the director or senior manager is not a party to the derivative, the nature of the relevant interest inthe derivative: Not applicableCertificationI certify that, to the best of my knowledge and belief, the information contained in this disclosure iscorrect and that I am duly authorised to make this disclosure by all persons for whom it is made.Signature of director or officer:Date of signature: 14-Jul-21----- End of picture text -----